ArticleClinical kidney journal2019
Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome.
Article in Clinical kidney journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immunosuppression for adult steroid-dependent or frequently relapsing nephrotic syndrome: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis.BMC nephrology · 2020Pooled it
- Efficacy of Rituximab as Adjunctive Therapy to Immunosuppressive Agents in Adult Primary Focal Segmental Glomerulosclerosis.Kidney international reports · 2025Article
- Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series.Kidney international reports · 2025Article
- Efficacy and Safety of Rituximab in Treating Adult Patients with Minimal Change Disease and Focal Segmental Glomerulosclerosis: A Prospective Study Compared with Glucocorticoids.Drug design, development and therapy · 2025Article
- Clinical profile, treatment response, and outcomes in adult primary focal segmental glomerulosclerosis: A single-center experience.Clinical nephrology · 2025Article
- Forging the Future: B Cell Activating Factor's Impact on Nephrotic Syndrome.The Malaysian journal of medical sciences : MJMS · 2024Review
- The Pathogenesis of Nephrotic Syndrome: A Perspective from B Cells.Kidney diseases (Basel, Switzerland) · 2024Review
- Rituximab treatment for refractory nephrotic syndrome in adults: a multicenter retrospective study.Renal failure · 2023Article
- Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS.Scientific reports · 2023Article
- Rituximab therapy in adults with steroid-dependent nephrotic syndrome.Archives of medical science : AMS · 2023Review
- The Role of Rituximab in Primary Focal Segmental Glomerular Sclerosis of the Adult.Kidney international reports · 2022Article
- Rituximab for Adults With Multi-Drug Resistant Focal Segmental Glomerulosclerosis: A Case Series and Review of the Literature.Canadian journal of kidney health and disease · 2022Article
- Rituximab Therapy for Adults with Nephrotic Syndromes: Standard Schedules or B Cell-Targeted Therapy?Journal of clinical medicine · 2021Review
- Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease.BMC nephrology · 2021Article
- Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis.Clinical kidney journal · 2021Review
- Article
- Clinical Response and Pattern of B cell Suppression with Single Low Dose Rituximab in Nephrology.Kidney360 · 2020Article
- Autoimmunity in Focal Segmental Glomerulosclerosis: A Long-Standing Yet Elusive Association.Frontiers in medicine · 2020Review
- Rituximab in Steroid-Dependent Podocytopathies.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with frequently relapsing (FR), steroid-dependent (SD) and steroid-resistant (SR) nephrotic syndrome are a therapeutic challenge with limited treatment options. Here, we retrospectively analyze the efficacy and safety of rituximab-induced continuous B-cell depletion in these populations.
methodsPatients were included if they were at least 18 years of age and had FR, SD or SR minimal change disease (MCD) or primary focal segmental glomerulosclerosis (FSGS) and were treated with a strategy of continuous B-cell depletion. Partial remission (PR) was defined as a urinary protein:creatinine ratio (UPCR) of ≤3.5 g/g and a 50% reduction in the UPCR from baseline. Complete remission (CR) was defined as a UPCR ≤0.3 g/g.
resultsWe identified 20 patients with MCD (
conclusionContinuous B-cell depletion is a therapeutic option in the management of complicated nephrotic syndrome. Additional studies are needed to clarify the utility of this strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.